Eli Lilly and Company (BKK:LLY80)

Market Cap	29.66T
Revenue (ttm)	1.93T
Net Income (ttm)	597.91B
Shares Out	n/a
EPS (ttm)	663.84
PE Ratio	49.61
Forward PE	33.90
Dividend	0.01 (0.39%)
Ex-Dividend Date	Nov 14, 2025

Volume	110,570
Average Volume	10,783,313
Open	1.680
Previous Close	1.660
Day's Range	1.670 - 1.690
52-Week Range	1.010 - 1.690
Beta	n/a
RSI	73.19
Earnings Date	Oct 30, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Pharmaceutical Preparations
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: LLY80

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD